by | May 12, 2025 | Singh, Nathan
— Published Date: 12/24/2024
Value proposition: An advanced CAR-T cell therapy engineered to reduce T cell exhaustion, enhancing durability and effectiveness in cancer treatment by overcoming one of the leading causes of long-term treatment failure.
Technology Description
Researchers at Washington…
by | Mar 6, 2025 | Cooper, Matthew, DiPersio, John
— Value Proposition: Engineered iNKT cells with potential as a “universal” source of immune effector cells to treat cancer.
Technology Description
Researchers at Washington University in St. Louis have developed a new composition of matter that uses gene-edited invariant natural kill…
by | Mar 6, 2025 | Cooper, Matthew, DiPersio, John
— Value Proposition: Engineered iNKT cells with potential as a “universal” source of immune effector cells to treat cancer.
Technology Description
Researchers at Washington University in St. Louis have developed a new composition of matter that uses gene-edited invariant natural kill…
by | Jan 8, 2025 | Dantas, Gautam, Gorushi, Olivia, Helmink, Beth, Kwak, Suryang, Prusa, Jerome, Wallace, Miranda
— Published date: 1/9/2025
Value Proposition: Genetically engineered yeast used to treat gastrointestinal tumors through the delivery of immune checkpoint inhibitor (ICI) proteins.
Technology Description
Researchers at Washington University in St. Louis have developed a genetically engineered …
by | Dec 19, 2024 | Chou, Chun, Egawa, Takeshi
— Published Date: 12/19/2024
Value Proposition: This invention utilizes a protein to enhance T cell expansion for CAR-T cell therapy and other adoptive cellular immunotherapy.
Technology Description
Researchers at Washinton University in St. Louis have developed a mutant AP4 protein that is desig…